Weekly Docetaxel and Prednisolone versus Prednisolone Alone in Androgen-Independent Prostate Cancer: A Randomized Phase II Study

European Urology

Volumn 52, Issue 6, 2007, Pages 1691-1699

  Fosså, Sophie D ^a,b   Jacobsen, Anne Birgitte ^a   Ginman, Claes ^c   Jacobsen, Inga N ^d   Overn, Sissel ^e   Iversen, Jon R ^f   Urnes, Thomas ^g   Dahl, Alv A ^a,b   Veenstra, Marijke ^a   Sandstad, Berit ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c LSK General Hospital   (Sweden)

^d STAVANGER UNIVERSITY HOSPITAL   (Norway)

^e Buskerud Central Hospital   (Norway)

^f ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^g Vestfold Central Hospital   (Norway)

Author keywords

Androgen independent prostate cancer; Prednisolone; Prostate specific antigen response; Survival; Taxotere

Indexed keywords

CORTICOSTEROID; DOCETAXEL; METHYLPREDNISOLONE; PREDNISOLONE;

ABDOMINAL PAIN; ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; GASTROINTESTINAL TOXICITY; HEART ATRIUM FLUTTER; HUMAN; HYPERTENSION; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAIL COLOR; NAUSEA; NEUTROPENIA; ONYCHOLYSIS; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH ULCER; STOMATITIS; STROKE; TASTE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN;

EID: 35748938220     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.01.104     Document Type: Article

References (24)

1. Clarke N.W., and Wylie J.P. Chemotherapy in hormone refractory prostate cancer: where do we stand?. Eur Urol 46 (2004) 709-711
2. Fosså S.D., Slee P.H.T., Brausi M., et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European Organization for Research and Treatment of Cancer Genitourinary Group. J Clin Oncol 19 (2001) 62-71
3. Tannock I.F., Osoba D., Stockier M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14 (1996) 1756-1764
4. Kantoff P.W., Halabi S., Conaway M., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 Study. J Clin Oncol 17 (1999) 2506-2513
5. Berruti A., Mosca A., Bitossi R., et al. Feasibility of 21-day continuous infusion of epirubicin in hormone-refractory prostate cancer patents. Anticancer Res 25 (2005) 4475-4479
6. van Angel G., Kurth K.H., Rietbroek R.L., and van De Velde-Muusers J.A. Quality of life assessment in patients with hormone-resistant prostate cancer treated with epirubicin or with epirubicin plus medroxy progesterone acetate: is it feasible?. Eur Urol 38 (2000) 259-264
7. Iversen P., Rasmussen F., Asmussen C., et al. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group. J Urol 157 (1997) 929-934
8. Beer T.M., Pierce W.C., Lowe B.A., and Henner W.D. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12 (2001) 1273-1279
9. Berry W., Dakhil S., Gregurich M.A., and Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28 Suppl 15 (2001) 8-15
10. Friedland D., Cohen J., Miller Jr. R., et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 26 Suppl 17 (1999) 19-23
11. Picus J., and Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 26 Suppl 17 (1999) 14-18
12. EORTC Data Center. Phase II Trials in the EORTC. Eur J Cancer 33 (1997) 1361-1363
13. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
14. Petrylak D.P., Tangen C.M., Hussain M.H.A., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
15. Trotti A., Byhardt R., Stetz J., et al. Common toxicity criteria, version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Rad Oncol Biol Phys 47 (2000) 13-47
16. Bubley G.J., Carducci M., Dahut W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17 (1999) 3461-3467
17. Hedlund P.O., Ala-Opas M., Brekkan E., et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer. Scand J Urol Nephrol 36 (2002) 405-413
18. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993) 365-376
19. Osoba D., Rodrigues G., Myles J., et al. Interpreting the significance of changes in health-related quality of life scores. J Clin Oncol 16 (1998) 139-144
20. Kelly W.M., Scher H.I., Mazamdar M., et al. Prostate specific antigen as a measure of disease outcome in metastatic hormone refractory prostate cancer. J Clin Oncol 4 (1993) 607-615
21. Fizazi K., Thuret R., Theodore C., et al. Early PSA rise subsequently followed by PSA decline is a common event in prostate cancer patient responders to chemotherapy. Ann Oncol 15 Suppl 3 (2004) 427
22. Fosså S.D., Vaage S., Letocha H., et al. Liposomal doxorubicin (CaelyxR) in symptomatic androgen-independent prostate cancer (AIPC): delayed response and flare phenomenon should be considered. Scand J Urol Nephrol 36 (2002) 34-39
23. Scher H.I., Eisenberger M., D'Amico A.V., et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the prostate-specific antigen working group. J Clin Oncol 22 (2004) 537-556
24. Scotté F., Tourani J.M., Banu E., et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 23 (2005) 4424-4429